Home » Topics » Disease categories and therapies » Inflammatory

Inflammatory
RSS

AM-095 displays antifibrotic activity in vivo

Jan. 13, 2011

AZD-9773 enters phase IIb trial in patients with severe sepsis and/or septic shock

Oct. 26, 2010

Almirall identifies new naphthyridine N-oxide as anti-inflammatory agent

Sep. 21, 2010

Positive outcome to decentralized procedure for European approval of Twinject

Sep. 1, 2010

Novel LPA1 receptor antagonists developed at Amira

July 7, 2010

Omeros selects clinical candidate for MASP-2 antibody program

May 14, 2010

Osiris achieves milestone for remestemcel-L development progress in Japan

April 29, 2010

DMC recommends continued enrollment in eritoran phase III trial for severe sepsis

March 26, 2010

Phase I trial of deferoxamine in acute cerebral hemorrhage currently recruiting participants

March 12, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...